TY - JOUR
T1 - Impact of COVID-19 Mandatory Lockdown Measures on Cognitive and Neuropsychiatric Symptoms in Persons with Alzheimer's Disease in Lima, Peru
AU - Custodio, Nilton
AU - Malaga, Marco
AU - Montesinos, Rosa
AU - Chambergo, Diego
AU - Baca, Fiorella
AU - Castro, Sheila
AU - Carbajal, Juan C.
AU - Herrera, Eder
AU - Lira, David
AU - Diaz, Monica M.
AU - Lanata, Serggio
N1 - Publisher Copyright:
© 2023 Bentham Science Publishers.
PY - 2023
Y1 - 2023
N2 - Background: Neuropsychiatric symptoms (NPS) in patients with Alzheimer’s disease (AD) worsened during the COVID-19 lockdowns, but their progression thereafter is unknown. We present the first longitudinal study tracking them before, during, and after restrictions. Objectives: To describe the effect of the COVID-19 mandatory lockdowns on Cognitive and Neuro-psychiatric symptoms in patients with Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD). Methods: Cohort of 48 patients with amnestic MCI and 38 with AD in Lima, Peru. They received three rounds of cognitive (RUDAS, CDR, M@T), behavioral (NPI), and functional (ADCS-ADL) as-sessments. We assessed the change in score means across the time points and for each domain of NPS and tracked the changes in individual patients. Results: RUDAS declined 0.9 (SD 1.0) from baseline to lockdown and 0.7 (SD 1.0) after restrictions. M@T declined 1.0 (SD 1.5) from baseline to lockdown and 1.4 (SD 2.0) after restrictions. CDR worsened in 72 patients (83.72%) from baseline to post-lockdown. NPI worsened by 10 (SD 8.3) from baseline to lockdown but improved by 4.8 (SD 6.4) after restrictions. Proportionally, 81.3% of all patients had worsened NPS during the lockdowns, but only 10.7% saw an increase thereafter. Improvement was statistically significant for specific NPS domains except hallucinations, delusions, and appe-tite changes. Anxiety, irritability, apathy, and disinhibition returned to baseline levels. Conclusion: Following confinement, cognition continued to decline, but NPS demonstrated either stability or improvement. This highlights the role modifiable risk factors may have on the progression of NPS.
AB - Background: Neuropsychiatric symptoms (NPS) in patients with Alzheimer’s disease (AD) worsened during the COVID-19 lockdowns, but their progression thereafter is unknown. We present the first longitudinal study tracking them before, during, and after restrictions. Objectives: To describe the effect of the COVID-19 mandatory lockdowns on Cognitive and Neuro-psychiatric symptoms in patients with Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD). Methods: Cohort of 48 patients with amnestic MCI and 38 with AD in Lima, Peru. They received three rounds of cognitive (RUDAS, CDR, M@T), behavioral (NPI), and functional (ADCS-ADL) as-sessments. We assessed the change in score means across the time points and for each domain of NPS and tracked the changes in individual patients. Results: RUDAS declined 0.9 (SD 1.0) from baseline to lockdown and 0.7 (SD 1.0) after restrictions. M@T declined 1.0 (SD 1.5) from baseline to lockdown and 1.4 (SD 2.0) after restrictions. CDR worsened in 72 patients (83.72%) from baseline to post-lockdown. NPI worsened by 10 (SD 8.3) from baseline to lockdown but improved by 4.8 (SD 6.4) after restrictions. Proportionally, 81.3% of all patients had worsened NPS during the lockdowns, but only 10.7% saw an increase thereafter. Improvement was statistically significant for specific NPS domains except hallucinations, delusions, and appe-tite changes. Anxiety, irritability, apathy, and disinhibition returned to baseline levels. Conclusion: Following confinement, cognition continued to decline, but NPS demonstrated either stability or improvement. This highlights the role modifiable risk factors may have on the progression of NPS.
KW - Alzheimer Disease
KW - COVID-19
KW - mandatory lock-down
KW - neuropsychiatric symptoms
KW - quarantine
KW - stay-at-home orders
UR - http://www.scopus.com/inward/record.url?scp=85164256324&partnerID=8YFLogxK
U2 - 10.2174/1567205020666230417103216
DO - 10.2174/1567205020666230417103216
M3 - Artículo
C2 - 37073648
AN - SCOPUS:85164256324
SN - 1567-2050
VL - 20
SP - 80
EP - 88
JO - Current Alzheimer Research
JF - Current Alzheimer Research
IS - 2
ER -